Next-Generation BTK Inhibitors and Why We Need Them

[Jm954]

Source: Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management October 2019

Whilst Ibrutinib has been a life saver for patients a very significant number have to suspend or stop treatment because of side effects (AEs) .

Specific adverse events (AEs), include myalgias, arthralgias, rash, bruising and, less commonly, serious bleeding, hypertension, or atrial fibrillation. Dose adjustments of ibrutinib can often help alleviate many of these AEs, but some can be dose limiting for individual patients.

This article looks at what we need from the next generation of BTK inhibitors and goes into some detail about what is on the horizon. They include the following: Improving Tolerability With More Selective BTK Inhibitors, Overcoming Acquired BTK inhibitor Resistance and the Potential for Fixed-Duration BTK Inhibitor Therapy.

More detail here: clinicaloptions.com/oncolog...

Jackie

[DebKat999]

Thank you Jackie. I have several existing medical issues which have made me question my ability to take Ibrutinib when it comes time for treatment. Information just like this is always of great interest to me, and I'm sure for others like me as well.

Debbie X